Literature DB >> 22169337

TNF superfamily in inflammatory disease: translating basic insights.

Michael Croft1, Wei Duan, Heonsik Choi, So-Young Eun, Shravan Madireddi, Amit Mehta.   

Abstract

The tumor necrosis factor (TNF) and TNF receptor superfamilies (TNFSF and TNFRSF) consist of approximately 50 membrane and soluble proteins that can modulate cellular function. Most of these molecules are expressed by or can target cells of the immune system, and they have a wide range of actions including promoting cellular differentiation, survival, and production of inflammatory cytokines and chemokines. Emerging data show that TNFSF ligand-receptor signaling pathways are active in inflammatory and autoimmune disease. Furthermore, several genetic polymorphisms in TNFSF and TNFRSF associate with susceptibility to developing disease. Here, we examine recent data regarding the potential of these molecules as targets for therapy of autoimmune and inflammatory disease. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169337      PMCID: PMC3299395          DOI: 10.1016/j.it.2011.10.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  79 in total

1.  CD40L induces inflammation and adipogenesis in adipose cells--a potential link between metabolic and cardiovascular disease.

Authors:  Anna Missiou; Dennis Wolf; Isabel Platzer; Sandra Ernst; Carina Walter; Philipp Rudolf; Katja Zirlik; Natascha Köstlin; Florian K Willecke; Christian Münkel; Uwe Schönbeck; Peter Libby; Christoph Bode; Nerea Varo; Andreas Zirlik
Journal:  Thromb Haemost       Date:  2010-02-19       Impact factor: 5.249

2.  CD153 in rheumatoid arthritis: detection of a soluble form in serum and synovial fluid, and expression by mast cells in the rheumatic synovium.

Authors:  Ricardo F S Carvalho; Ann-Kristin Ulfgren; Marianne Engström; Erik af Klint; Gunnar Nilsson
Journal:  J Rheumatol       Date:  2009-01-22       Impact factor: 4.666

3.  The TNF superfamily in 2009: new pathways, new indications, and new drugs.

Authors:  Malú G Tansey; David E Szymkowski
Journal:  Drug Discov Today       Date:  2009-10-28       Impact factor: 7.851

Review 4.  Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.

Authors:  Ezogelin Oflazoglu; Iqbal S Grewal; Hanspeter Gerber
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 5.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

6.  APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response.

Authors:  Yanping Xiao; Seiichi Motomura; Eckhard R Podack
Journal:  Eur J Immunol       Date:  2008-12       Impact factor: 5.532

7.  A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.

Authors:  Xun Sun; Shinichi Somada; Kensuke Shibata; Hiromi Muta; Hisakata Yamada; Hirofumi Yoshihara; Kuniomi Honda; Kazuhiko Nakamura; Ryhoichi Takayanagi; Kenzaburo Tani; Eckhard R Podack; Yasunobu Yoshikai
Journal:  Gastroenterology       Date:  2007-11-04       Impact factor: 22.682

8.  The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.

Authors:  F Meylan; Y-J Song; I Fuss; S Villarreal; E Kahle; I-J Malm; K Acharya; H L Ramos; L Lo; M M Mentink-Kane; T A Wynn; T-S Migone; W Strober; R M Siegel
Journal:  Mucosal Immunol       Date:  2010-10-27       Impact factor: 7.313

9.  Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation.

Authors:  Lei Fang; Becky Adkins; Vadim Deyev; Eckhard R Podack
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

10.  The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis.

Authors:  Melanie Jane Bull; Anwen Siân Williams; Zarabeth Mecklenburgh; Claudia Jane Calder; Jason Peter Twohig; Carole Elford; Bronwen Alice James Evans; Tania F Rowley; Tomasz J Slebioda; Vadim Y Taraban; Aymen Al-Shamkhani; Eddie Chung Yern Wang
Journal:  J Exp Med       Date:  2008-09-29       Impact factor: 14.307

View more
  78 in total

1.  Vibrio cholerae Cholix Toxin-Induced HepG2 Cell Death is Enhanced by Tumor Necrosis Factor-Alpha Through ROS and Intracellular Signal-Regulated Kinases.

Authors:  Kohei Ogura; Yasuhiro Terasaki; Tohru Miyoshi-Akiyama; Mika Terasaki; Joel Moss; Masatoshi Noda; Kinnosuke Yahiro
Journal:  Toxicol Sci       Date:  2017-04-01       Impact factor: 4.849

2.  Tumor necrosis factor family member LIGHT acts with IL-1β and TGF-β to promote airway remodeling during rhinovirus infection.

Authors:  A K Mehta; T Doherty; D Broide; M Croft
Journal:  Allergy       Date:  2018-03-01       Impact factor: 13.146

3.  Basophil-associated OX40 ligand participates in the initiation of Th2 responses during airway inflammation.

Authors:  Caixia Di; Xiaoliang Lin; Yanjie Zhang; Wenwei Zhong; Yufan Yuan; Tong Zhou; Junling Liu; Zhenwei Xia
Journal:  J Biol Chem       Date:  2015-04-03       Impact factor: 5.157

Review 4.  Regulation of tumour necrosis factor signalling: live or let die.

Authors:  Dirk Brenner; Heiko Blaser; Tak W Mak
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

Review 5.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

6.  Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells.

Authors:  Maria-Luisa del Rio; Carlos Fernandez-Renedo; Olivier Chaloin; Stefanie Scheu; Klaus Pfeffer; Yasushi Shintani; Jose-Antonio Perez-Simon; Pascal Schneider; Jose-Ignacio Rodriguez-Barbosa
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

7.  Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets.

Authors:  Eun Jee Kim; Jae Geun Lee; Joon Ye Kim; Seung Hwan Song; Dong Jin Joo; Kyu Ha Huh; Myoung Soo Kim; Beom Seok Kim; Yu Seun Kim
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

8.  Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members.

Authors:  Julia T Warren; Christopher A Nelson; Corinne E Decker; Wei Zou; Daved H Fremont; Steven L Teitelbaum
Journal:  Sci Signal       Date:  2014-08-19       Impact factor: 8.192

9.  The promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia).

Authors:  Lakshmi Ganesan; Peter Buchwald
Journal:  J Mol Recognit       Date:  2013-04       Impact factor: 2.137

Review 10.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.